The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis

Table 3 BAb/NAb status in patients with both initial and last assessments

	Status at last assessment, n (%)
Status at initial assessment	BAb(−)	BAb(+)/NAb(−)	BAb(+)/NAb(+) moderate	BAb(+)/NAb(+) high
BAb(−), n = 624	570 (91.4)^*	40 (6.4)^‡	7 (1.1)^‡	7 (1.1)^‡
BAb(+)/NAb(−), n = 222	81 (36.5)^†	122 (55.0)*	16 (7.2)^‡	3 (1.4)^‡
BAb(+)/NAb(+) moderate, n = 69	14 (20.3)^†	14 (20.3)^†	29 (42.0)*	12 (17.4)^‡
BAb(+)/NAb(+) high, n = 130	9 (6.9)^†	2 (1.5)^†	9 (6.9)^†	110 (84.6)*

*Patients who maintained titre.
†Decrease in titre.
‡Increase in titre.
BAb(−), serum binding antibody negative; NAb(−), serum neutralizing antibody negative.
NOTE: BAb(−), <4 units; BAb(+), >4 units; NAb(−), <20 units; NAb(+) moderate, ≥20 units to <100 units; NAb(+) high, ≥100 units.
BAb, serum binding antibodies; NAb, serum neutralizing antibodies.

ISSN: 1471-2377